Precision medicine for non-small cell lung cancer (NSCLC)
With precision medicine becoming a more integral component of NSCLS treatment, molecular testing is an important step in helping researchers, pathologists, and oncologists understand the genetic underpinnings of this disease. Pathologists commonly use immunohistochemistry and next-generation sequencing to characterize lessons and refine diagnoses, while circulating tumour DNA analysis has emerged as a promising, non-invasive companion diagnostic.
This white paper explores the roles IHC, NGS and ctDNA play in NSCLC precision medicine therapy development, as well as how they help healthcare providers determine the most effective treatment regimens for their patients. Download to find out more.